Evidence map›Paper›PMID 33919930›Full record

ArticleCancers2021

Prediction of Microscopic Metastases in Patients with Metachronous Oligo-Metastases after Curative Treatment of Non-Small Cell Lung Cancer: A Microsimulation Study.

Henri B Wolff, Leonie Alberts, Elisabeth A Kastelijn, Naomi E Verstegen, Sherif Y El Sharouni, Franz M N H Schramel, Rein Vos, Veerle M H Coupé

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Cost-Effectiveness of Surveillance Scanning Strategies after Curative Treatment of Non-Small-Cell Lung Cancer.Medical decision making : an international journal of the Society for Medical Decision Making · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Henri B WolffDepartment of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC, Location VUmc, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0003-3417-6955
Leonie AlbertsDepartment of Pulmonology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.ORCID 0000-0002-1771-6182
Elisabeth A KastelijnDepartment of Pulmonology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
Naomi E VerstegenDepartment of Radiation Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Sherif Y El SharouniDepartment of Radiation Oncology, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.
Franz M N H SchramelDepartment of Pulmonology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
Rein VosDepartment of Methodology & Statistics, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands.
Veerle M H CoupéDepartment of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC, Location VUmc, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0002-9553-9791

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metachronous oligo-metastatic disease is variably defined as one to five metastases detected after a disease-free interval and treatment of the primary tumour with curative intent. Oligo-metastases in non-small cell lung cancer (NSCLC) are often treated with curative intent. However additional metastases are often detected later in time, and the 5-year survival is low. Burdensome surgical treatment in patients with undetected metastases may be avoided if patients with a high versus low risk of undetected metastases can be separated. Because there is no clinical data on undetected metastases available, a microsimulation model of the development and detection of metastases in 100,000 hypothetical stage I NSCLC patients with a controlled primary tumour was constructed. The model uses data from the literature as well as patient-level data. Calibration was used for the unobservable model parameters. Metastases can be detected by a scheduled scan, or an unplanned scan when the patient develops symptoms. The observable information at time of detection is used to identify subgroups of patients with a different risk of undetectable metastases. We identified the size and number of detected oligo-metastases, as well as the presence of symptoms that are the most important risk predictors. Based on these predictors, patients could be divided into a low-risk and a high-risk group, having a model-based predicted probability of 8.1% and 89.3% to have undetected metastases, respectively. Currently, the model is based on a synthesis of the literature data and individual patient-level data that were not collected for the purpose of this study. Optimization and validation of the model is necessary to allow clinical usability. We describe the type of data that needs to be collected to update our model, as well as the design of such a validation study.

Indexed as

non-small cell lung canceroligo-recurrenceprediction model

Identifiers

PMID33919930
PMCPMC8070977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.